The biotech will begin clinical trials of its lead drug candidates in ROS1-positive and ALK-positive non-small cell lung cancer in 2021 and 2022, respectively.
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.